Key points are not available for this paper at this time.
Abstract
Liver metastasis and sex are predictors of survival benefit following the addition of a PD-1 antibody to regorafenib in patients with MSS mCRC.
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer | Synapse